Diabetes News

Adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists, according to observational data published in JAMA Network Open.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

A new drug application for sotagliflozin as an adjunct to insulin therapy for adults with type 1 diabetes and chronic kidney disease has been resubmitted to the FDA, according to a press release.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.

ORLANDO — Semaglutide use was associated with significant reductions in worsening of kidney disease, cardiovascular events and all-cause death vs. placebo for adults with type 2 diabetes regardless of concomitant use of SGLT2 inhibitors.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Melanie Betz, MS, RD, CSR, FNKF, FAND, about preventing kidney stones through diet and nutrition.

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, presents updated multispecialty practice recommendations for diabetes, cardiorenal and metabolic diseases at the Heart in Diabetes CME Conference.

Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.

Patients with type 2 diabetes and chronic kidney disease receiving empagliflozin were less likely to experience a decline in eGFR compared with patients taking placebo, results from a newly published study show.